High viscosity grade Nisso HPC-H (hydroxypropyl cellulose) offers advantages as a controlled release polymer when compared to HPMC in a sustained release matrix tablet application.
High viscosity grade Nisso HPC-H (hydroxypropyl cellulose) offers advantages as a controlled release polymer when compared to HPMC in a sustained release matrix tablet application. In a direct compression application, HPC-H (fine powder type) sustains drug release more effectively than HPMC in the case of equivalent viscosity of the two polymers. Further, HPC-H has equivalent control release performance to HPMC 100000 while HPC-H has much lower viscosity, and this result is found when the tablet is prepared using either direct compression or wet granulation method.
Fig. 1: Effect of CR material (HPC vs HPMC, direct compression method)
Effect of CR Material (DC Method) is as shown in Fig 1. In the case of DC method, HPC-H-FP sustained drug release more than HPMC 4000, and showed equivalent release control performance to HPMC 100000 while its viscosity was much lower.
Fig 2: Effect of CR Material (HPC vs. HPMC, wet granulation method)
Effect of CR Polymer (WG Method) is as shown in Fig. 2. In the case of WG method, much difference was not seen in comparison of drug release from tablet prepared by HPC-H and HPC-H-FP. Also, Both HPC-H and HPC-H-FP showed equivalent release control performance to HPMC 100000. Drug release from tablet prepared by HPMC 4000 was much faster than the others.
Click here to download a white paper with complete data.
Contact info:
Catherine Cote
c.cote@nissoamerica.com
Nisso America Inc.
88 Pine Street, 14th Fl
New York, NY 10005
+1-212-490-0350
www.nissoexcipients.com
Nisso Chemical Europe GmbH
Naoki Kuwada
kuwada@nisso-chem.de
+49-(0)-211-1306686-0
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
PacBio Chosen as Tech Partner for Global Alzheimer’s Disease Research Project
April 23rd 2025The project, the North African Dementia Registry, will unite multiple entities for the purpose of developing a comprehensive dataset to advance the research community’s understanding of Alzheimer’s disease and other dementias in diverse populations.